Ginkgo Bioworks DNA Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $3.6M— | —— | $5.74M-5.6% | $6.08M0.0% | $6.08M— | ||
| $19.47M-41.7% | $33.4M-14.0% | $38.84M-21.7% | $49.6M+29.8% | $38.23M-12.8% | ||
| $3.1M— | —— | —— | —— | $4.09M— | ||
| $16.38M— | —— | —— | —— | $34.14M— | ||
| 84.1%— | —— | —— | —— | 89.3%— | ||
| $49.92M-0.4% | $50.13M-27.7% | $69.35M+29.9% | $53.37M-24.7% | $70.92M-7.1% | ||
| $37.83M-17.8% | $46.01M+2.4% | $44.95M+3.9% | $43.28M+9.0% | $39.72M-30.7% | ||
| $90.85M— | —— | —— | —— | $119.2M— | ||
| -$71.37M-0.9% | -$70.75M+21.4% | -$90.02M-37.3% | -$65.54M+19.1% | -$80.97M+21.8% | ||
| -366.5%-155pp | -211.9%+19.9pp | -231.8%-99.7pp | -132.1%+79.7pp | -211.8%+24.5pp | ||
| -$4.77M— | —— | $9.26M+86.8% | $4.96M+320% | -$2.25M— | ||
| -$76.14M+6.5% | -$81.39M-0.8% | -$80.75M-33.3% | -$60.58M+27.2% | -$83.22M+22.8% | ||
| -$80K+87.6% | -$643K-64,400% | $1K+100% | -$283K-422% | $88K+127% | ||
| -$58.58M-2.6% | -$57.09M+24.7% | -$75.85M-54.2% | -$49.2M+25.6% | -$66.15M+24.8% | ||
| -300.8%-130pp | -170.9%+24.4pp | -195.3%-96.1pp | -99.2%+73.8pp | -173%+27.6pp | ||
| -$71.37M-0.9% | -$70.75M+21.4% | -$90.02M-37.3% | -$65.54M+19.1% | -$80.97M+21.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Ginkgo Bioworks's revenue?
- Ginkgo Bioworks (DNA) generated $141.3M in revenue over the trailing twelve months, down 37.8% year over year.
- Is Ginkgo Bioworks profitable?
- Ginkgo Bioworks is not currently profitable: it reported a net loss of $304.4M over the trailing twelve months, a -215.4% net margin.
- Where does Ginkgo Bioworks's income statement data come from?
- Every line is extracted from Ginkgo Bioworks's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
